CORD Rare Disease Patient Survey

Similar documents
OxyContin in the 90 days prior to it being discontinued.

Physical Medicine & Rehabilitation. Physical Medicine and Rehabilitation Profile

2017 JOB MARKET & EMPLOYMENT SURVEY EXECUTIVE SUMMARY

Provincial Projections of Arthritis or Rheumatism, Special Report to the Canadian Rheumatology Association

Economic Burden of Musculoskeletal Diseases in Canada

Recently, the Institute of Musculoskeletal Health and

Geriatric Medicine. Geriatric Medicine Profile

ADHD and Education Survey March The Centre for ADHD Awareness, Canada

DERMATOLOGY PROFILE GENERAL INFORMATION

West Nile virus and Other Mosquito borne Diseases National Surveillance Report English Edition

Neurology. Neurology Profile

Critical Care Medicine. Critical Care Medicine Profile

Estimating the volume of Contraband Sales of Tobacco in Canada

Mental Health Statistics, to

Physiotherapists in Canada, 2011 National and Jurisdictional Highlights

Medical Aid in Dying A Year of Change

ABOUT FMC MEMBERSHIP:

CHAPTER 4: Population-level interventions

LIST OF FIGURES INTRODUCTION

Occupational Noise Exposure

Health Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods

Advance Care Planning

General Internal Medicine. General Internal Medicine Profile

Smoking Cessation and the Workplace

Health Interventions in Ambulatory Cancer Care Centres

Health Canada Endorsed Important Safety Information on Infanrix Hexa

Cost-effectiveness in FASD prevention. Egon Jonsson, Institute of Health Economics, Edmonton, Alberta, Canada

Macrolides in community-acquired pneumonia and otitis media Canadian Coordinating Office for Health Technology Assessment

Appendix B Fracture incidence and costs by province

Membership Application

GERIATRIC MEDICINE PROFILE

Waiting Your Turn Wait Times for Health Care in Canada, 2017 Report

THE CANADIAN GUIDELINES AND THE INTERDISCIPLINARY CLINICAL CAPACITY OF CANADA TO DIAGNOSE FETAL ALCOHOL SPECTRUM DISORDER

Waiting Your Turn. Wait Times for Health Care in Canada, 2018 Report. by Bacchus Barua and David Jacques. with Antonia Collyer

Influenza Vaccination Coverage in British Columbia Canadian Community Health Survey 2011 & 2012

Methadone 8.3. Dispensing (Ontario) This document describes the recommended way to setup and dispense Methadone mixtures.

Report from the National Diabetes Surveillance System:

PROFILE AND PROJECTION OF DRUG OFFENCES IN CANADA. By Kwing Hung, Ph.D. Nathalie L. Quann, M.A.

Challenges associated with the diagnosis of ASD

MAJOR RELEASES OTHER RELEASES PUBLICATIONS RELEASED 5

The 2012 SAGE Wait Time Program: Survey of Access to GastroEnterology in Canada Can J Gastroenterol 2013;27:83-9.

vaccination in Canada Bernard Duval, md, mph, frcpc Institut National de Santé Publique du Québec Québec, Canada Sevilla,

WORKPLACE SMOKING BAN POLICY

Antimicrobial Resistant Organisms (ARO) Surveillance SURVEILLANCE REPORT FOR DATA FROM JANUARY TO DECEMBER

ICD-10 Reciprocal Billing File Technical Specifications Reference Guide for Ontario Hospitals

Mina Tadrous, Diana Martins, Zhan Yao, Kimberly Fernandes, Samantha Singh, Nikita Arora, David Juurlink, Muhammad Mamdani and Tara Gomes

Demand for Ocular Tissue in Canada - Final Report

NATIONAL PALLIATIVE MEDICINE SURVEY DATA REPORT

Towards a Provincial Strategy

Canadian Association of Optometrists. January December March 2016

Mexico. Figure 1: Confirmed cases of A[H1N1] by date of onset of symptoms; Mexico, 11/07/2009 (Source: MoH)

Severe Acute Respiratory Syndrome (SARS) Lessons Learned

ORTHOPEDIC SURGERY PROFILE

November 5 to 11, 2017 (Week 45)

Poisoning and Poison Control Centres across Canada

Tamper-Resistant Properties of Drugs Regulations (TRPDR)

West Nile Virus and Other Mosquito-borne Diseases National Surveillance Report English Edition September 11 to September 17, 2016 (Week 37)

Myths and facts: Suicide Prevention in the Workplace. Centre for Suicide Prevention November 21 st, 2017

ENDOCRINOLOGY/METABOLISM PROFILE

Impaired driving statistics

OTOLARYNGOLOGY PROFILE

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018

TECHNOLOGY OVERVIEW: PHARMACEUTICALS

Supply, Distribution and Migration of Canadian Physicians, 2010

Drugs for Overactive Bladder (OAB)

Patient-Centred Research Priorities Relating to Healthcare of Frail Older Canadians

Telerehabilitation Resource Guide for Alberta Physiotherapists April 2018

Diabetes in our Communities:

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

The Case for Fluoridation In Orillia

Today s Speakers Robert Schwartz

Manitoba EMR Data Extract Specifications

West Nile Virus and Other Mosquito-borne Diseases National Surveillance Report English Edition September 18 to September 24, 2016 (Week 38)

YOUR SEASONAL FLU GUIDE

Appendix A: Introduction to Imaging Modalities for Which Data Were Collected in the 2017 Imaging Inventory

VACCINE COVERAGE IN CANADIAN CHILDREN

TRANSFUSION TRANSMITTED INJURIES SURVEILLANCE SYSTEM (TTISS): SUMMARY RESULTS. 1 P age

Sampling Methodology

Is the Canadian economy transitioning from raw materials to high-tech? Part 1. Alex Carrick, Chief Economist, ConstructConnect

Melanoma Treatment in the Adjuvant Setting

Implementing Rapid Response Teams (RRT) National Call September 13, 2007

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly

CHAPTER 3: Modifiable risk factors and diabetes self-care

One World, One Evidence-base, Many Decisions

Provincial and Territorial Smoke-Free Legislation Alberta

Canada s Inter agency Wild Bird Influenza Survey. Draft Proposal for the Survey Version 1 25 January 2010

Disclosures. What is Palliative Care? The Role of the S-LP in Palliative Care An Overview and Interactive Discussion.

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults

WEST NILE VIRUS AND OTHER MOSQUITO-BORNE DISEASE NATIONAL SURVEILLANCE REPORT

The Leading Global Provider of Fitness & Wellness Education

W H A T N A C D O E S

SUPPLY, DISTRIBUTION AND MIGRATION OF CANADIAN

A PERFECT STORM OF HEART DISEASE LOOMING ON OUR HORIZON 2010 HEART AND STROKE FOUNDATION ANNUAL REPORT ON CANADIANS HEALTH A PERFECT STORM 1

Canadian Academic Detailing Collaboration

Trends in adult obesity

Tuberculosis in Canada - Summary 2015

# Claims with disp.fee > 0. Average cost submitted by Rx**

Provincial. Physical Education. Nova Scotia.

Sustainable Solutions Report: A Focus on Pharmacist Medication Reviews

December 3 to 9, 2017 (Week 49)

Transcription:

CORD Rare Disease Patient Survey 7 March 2015 Powered by

491 Eng + 61 Fr = 552 Total Responses March 3, 2015

Q1: Who is answering this questionnaire? 534 Responses 3

Q3: What is gender of person with rare disease? 522 Responses 4

PROVINCIAL REPRESENTATION OF Respondents 561 respondents Alberta 8.4% British Columbia 12.5% Manitoba 1.5% New Brunswick 0.4% Newflnd//Lab 2.2% NW Territories 0.7% Nova Scotia 2.2% Nunavik 0.0% Ontario 54.2% PEI 0.0% Quebec 13.6% Saskatchewan 1.5% Yukon 0.4% Other 2.6% 5

Q6: How long after the first symptoms or suspicion of disease did it take to get an accurate diagnosis? 462 Responses 6

Q7: How many doctors did you see between the time of first manifestations or symptoms and the final diagnosis? 465 Responses 7

Q9: How many "wrong" or inaccurate diagnoses did you receive before the final "right" diagnosis? 462 Responses # Wrong Diagnoses % % 40.4% 35.2% 26.7% 25.9% 16.2% 18.5% 13.7% 13.0% 2.9% 7.4% 0 (none) 1 to 2 3 to 5 > 5 No diagnosis 8

Q.10 To what degree do you agree with the following statements about the information you have received about the rare disease. Right amount information at time of diagnosis 40.1% 25.5% 43.7% 48.9% Understand information from HCP 50.8% 68.1% 21.1% 17.0% Found rare disease information on Internet 71.6% 89.5% 10.7% 5.4% Given contact person or number 19.1% 10.6% 66.3% 80.8% Given patient organization or support group 20.5% 4.3% 68.1% 91.5% Know where to get info to deal with disease 53.7% 38.3% 29.5% 38.0% Have access to needed info at this time 57.3% 31.9% 36.4% 42.6% 9

Q11: To what degree do you agree with the following statements about information about rare diseases overall? GPS are aware & informed about rare diseases 5.2% 4.2% 81.0% 55.3% Paediatricians aware & informed about RDs 3.8% 17.0% 49.2% 31.9% Specialists have knowledge & expertise in RDs 26.0% 25.5% 53.0% 42.6% Researchers interested & engaged in RDs 28.8% 21.9% 36.4% 44.7% Educational services aware/informed re: RDs 20.5% 4.3% 68.1% 91.5% Employment services aware/informed re: RDs 1.3% 4.6% 80.6% 66.0% Disability services aware/informed re: RDs 7.9% 17.4% 66.4% 60.9% 10

Q12: To what degree do you agree with the following statements about the access to treatment and support you have received for the rare disease. Appropriate assessment & testing following diagnosis 59.9% 53.7% 28.1% 31.7% Access specialists & clinics for RD 37.0% 20.0% 50.4% 65.5% Access coordinator for clinics & specialists 24.8% 40.0% 53.0% 59.7% Access to appropriate drug treatments 40.1% 47.5% 35.7% 40.0% Access to non-drug treatments 31.4% 40.0% 33.7% 30.0% Received counselling with diagnosis 14.6% 10.0% 73.4% 80.0% Access to financial resources to deal with RD 21.0% 15.4% 58.8% 74.4% Access to palliative care, if needed 24.0% 15.4% 35.2% 33.4% 11

Q13: To what degree do you agree with the following statements about medicines for your rare disease? Aware of approved drugs for my rare disease 38.7% 42.1% 39.7% 34.2% Can access prescription drugs for my rare disease 35.8% 54.1% 46.2% 35.1% Aware of off-label drugs for my rare disease 31.5% 42.1% 33.8% 15.8% Can access off-label drugs for my rare disease 10.5% 29.4% 52.6% 40.0% Difficult or stressful to access drugs for my rare disease 44.0% 28.9% 28.3% 39.4% Have private drug plan for prescription drugs 37.7% 47.4% 41.0% 36.9% Drug plan does not cover some of my prescription drugs 29.0% 23.7% 36.9% 50.0% Unable to access drugs because costs or co-pay too high 28.5% 16.2% 39.3% 56.7% 12

Q14: Do you and your family incur personal costs related to care for your rare disease? 391 Responses 13

Q15: What is the amount your family spends annually related to care for your rare disease? 392 Responses 14

Q16: Is your rare disease a genetic (or inherited) condition? 447 Responses 15

Q17: To what degree do you agree with the following statements about genetic services for rare diseases. Received pre-natal counselling about genetic RD 8.0% 13.6% 47.3% 68.2% Received pre-natal screening for genetic RD 6.4% 4.8% 43.2% 71.4% Received newborn screening for genetic RD 5.9% 0% 46.3% 76.2% Received diagnosis, info & support for my RD 19.1% 10.6% 66.3% 52.7% Family got screening, testing, counselling for RD 17.9% 27.3% 49.3% 68.2% Family got post-natal support for RD 13.2% 31.9% 40.0% 78.2% 16

CORD Patient Survey Summary Findings Getting to Diagnosis Median time to diagnosis: 3 to 6 years 21% over 6 years Median number of specialists consulted: 3 to 5 10% over 11 specialists; 5% over 20 specialists Median number of wrong diagnosis: 1 to 2 40% more than 3 misdiagnoses; 15% more than 5 misdiagnoses Information at Diagnosis Only 40% got right amount of information at diagnosis Only 50% understood information from Healthcare professional Only 50% know where to get information needed Only 5% feel GPs and/or pediatricians have knowledge of rare diseases Only 25% feel specialists are knowledgeable about rare diseases 17

CORD Patient Survey Summary Findings Access to Treatment and Support Less than 40% have access to rare disease specialist or clinic Less than 40% have access to drug treatments Less than 30% have access to non-drug treatments Personal expenses to deal with rare disease 70% incur personal costs related to rare disease Personal costs for non-quebeckers about 60% more than for Quebeckers Average personal health services cost: $3,000 Average personal prescription drug costs: $2,300 Average OTC drug costs: $800 Average support services costs: $2,500 Average other costs: $6,500 Average total personal costs: $14,400 outside Quebec; $9,000 Quebec 18

THANK YOU! For More information please contact: Canadian Organization for Rare Disorders info@raredisorders.ca Powered by 19